

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
Segmented By Valence (Bivalent, Quadrivalent, Nonvalent, Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others), By Company and By Region

Market Report | 2022-12-01 | 113 pages | TechSci Research

AVAILABLE LICENSES:

- Single User License \$4900.00
- Multi-User License \$5900.00
- Custom Research License \$8900.00

Report description:

The global human papillomavirus vaccine market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing incidences of HPV-related diseases, and rise in initiatives by government and private organizations, which are curbing the growth of the market. Human papillomavirus infection is the most common sexually transmitted contamination caused by HPV-related cancers such as cervical, penile, and genital cancer. Human papillomavirus vaccines are immunizations that protect from certain type of human papillomavirus. It protects against either two, four or nine kinds of HPV. The other factors supporting the market's growth are, the increasing research for therapeutic vaccine, large number of clinical trials, increasing awareness and government investments, ease in approval of new HPV vaccines, and growing need to reduce HPV infections.

Increasing cases of Human Papillomavirus Diseases among the Population

Upsurge in the cases of HPV related diseases such as anal, oropharynx, and genital parts and growing demand for HPV vaccines, are projecting to propel the growth of the market, globally. There are just three types of vaccines in the market: bivalent,

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

tetravalent, and nonavalent. All the three vaccines are highly effective in avoiding infection with both virus types 16 and 18, which are liable for curing 70% of cervical cancer cases. According to the Centers for Disease Control and Prevention (CDC), in U.S, human papillomavirus is the most common sexually transmitted infection. Over 70% of vulvar and vaginal diseases, 60% of penile malignant growths, and 90% of anal cancer and cervical tumors are caused because of HPV. Moreover, in women, cervical cancer is very common among age between 9 to 30, which spur the need for HPV vaccine. For instance, according to the WHO, in 2017, cervical cancer is liable for over 2,50,000 deaths of women globally and 85% of these deaths occur in developing countries.

Increasing Initiatives by Government & Private Organizations

Over the past few years, governments of different nations and private organizations are taking several steps to bolster the growth of the market. Rising initiatives such as heavy investments on research and development, increase in awareness programs, extensive research actives and clinical trials and ease in approvals by the regulatory bodies, are the supporting factors for the market. For instance, recently, India launched the first quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer. Also, Profectus Biosciences, Inc., is in process to develop GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV. The vaccine is believed to be effective against seven HPV kinds. Furthermore, organizations, especially UNICEF, have made efforts to improve vaccine acceptance over the years. The impact of the Pan American Health Organization (PAHO) revolving fund and UNICEF supply division permits vaccinations to be acquired at lower prices for diverse nations.

Market Segmentation

The global human papillomavirus vaccine market is segmented into valence, disease indication, distribution channel, and company. Based on valence, the market is divided into bivalent, quadrivalent, nonvalent, and others. Based on disease indication, the market is divided into cervical cancer, anal cancer, vaginal cancer, penile cancer, vulvar cancer, and others. Based on distribution channel, the market is segmented into hospitals & clinics, governmental & non-governmental organizations, public & private alliances, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising prevalence of HPV-related diseases and better healthcare infrastructure in the country.

Market Players

Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Novartis AG, Inovio Pharmaceuticals, Inc., Xenetic Biosciences, Inc., Sanofi SA, and Bharat Biotech International Limited are some of the leading companies operating in the market.

Report Scope:

In this report, global human papillomavirus vaccine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

-□ Human Papillomavirus Vaccine Market, By Valence:

o□ Bivalent

o□ Quadrivalent

o□ Nonvalent

o□ Others

-□ Human Papillomavirus Vaccine Market, By Disease Indication:

o□ Cervical Cancer

o□ Anal Cancer

o□ Vaginal Cancer

o□ Penile Cancer

o□ Vulvar Cancer

o□ Others

-□ Human Papillomavirus Vaccine Market, By Distribution Channel:

o□ Hospitals & Clinics

o□ Governmental & Non-Governmental Organizations

o□ Public & Private Alliances

o□ Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

-□ Human Papillomavirus Vaccine Market, By Region:

o□ North America

-□ United States

-□ Canada

-□ Mexico

o□ Asia-Pacific

-□ China

-□ India

-□ Japan

-□ Australia

-□ South Korea

o□ Europe & CIS

-□ Germany

-□ France

-□ United Kingdom

-□ Spain

-□ Italy

o□ South America

-□ Brazil

-□ Argentina

-□ Colombia

o□ Middle East & Africa

-□ South Africa

-□ Saudi Arabia

-□ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Human Papillomavirus Vaccine Market

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

-□ Detailed analysis and profiling of additional market players (up to five).

Table of Contents:

1.□ Product Overview

2.□ Research Methodology

3.□ Impact of COVID-19 on Global Human Papillomavirus Vaccine Market

4.□ Voice of Customer

5.□ Executive Summary

6.□ Clinical Trial Analysis

7.□ Patent Analysis

8.□ Global Human Papillomavirus Vaccine Market Outlook

8.1.□ Market Size & Forecast

8.1.1.□ By Value

8.2.□ Market Share & Forecast

8.2.1.□ By Valence (Bivalent, Quadrivalent, Nonvalent, Others)

8.2.2.□ By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.2.3. By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others)
- 8.2.4. By Company (2021)
- 8.2.5. By Region
- 8.3. Market Map
- 9. North America Human Papillomavirus Vaccine Market Outlook
 - 9.1. Market Size & Forecast
 - 9.1.1. By Value
 - 9.2. Market Share & Forecast
 - 9.2.1. By Valence
 - 9.2.2. By Disease Indication
 - 9.2.3. By Distribution Channel
 - 9.2.4. By Country
 - 9.3. North America: Country Analysis
 - 9.3.1. United States Human Papillomavirus Vaccine Market Outlook
 - 9.3.1.1. Market Size & Forecast
 - 9.3.1.1.1. By Value
 - 9.3.1.2. Market Share & Forecast
 - 9.3.1.2.1. By Valence
 - 9.3.1.2.2. By Disease Indication
 - 9.3.1.2.3. By Distribution Channel
 - 9.3.2. Mexico Human Papillomavirus Vaccine Market Outlook
 - 9.3.2.1. Market Size & Forecast
 - 9.3.2.1.1. By Value
 - 9.3.2.2. Market Share & Forecast
 - 9.3.2.2.1. By Valence
 - 9.3.2.2.2. By Disease Indication
 - 9.3.2.2.3. By Distribution Channel
 - 9.3.3. Canada Human Papillomavirus Vaccine Market Outlook
 - 9.3.3.1. Market Size & Forecast
 - 9.3.3.1.1. By Value
 - 9.3.3.2. Market Share & Forecast
 - 9.3.3.2.1. By Valence
 - 9.3.3.2.2. By Disease Indication
 - 9.3.3.2.3. By Distribution Channel
- 10. Europe Human Papillomavirus Vaccine Market Outlook
 - 10.1. Market Size & Forecast
 - 10.1.1. By Value
 - 10.2. Market Share & Forecast
 - 10.2.1. By Valence
 - 10.2.2. By Disease Indication
 - 10.2.3. By Distribution Channel
 - 10.2.4. By Country
 - 10.3. Europe: Country Analysis
 - 10.3.1. France Human Papillomavirus Vaccine Market Outlook
 - 10.3.1.1. Market Size & Forecast
 - 10.3.1.1.1. By Value

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3.1.2.□Market Share & Forecast
 - 10.3.1.2.1.□By Valence
 - 10.3.1.2.2.□By Disease Indication
 - 10.3.1.2.3.□By Distribution Channel
- 10.3.2.□Germany Human Papillomavirus Vaccine Market Outlook
 - 10.3.2.1.□Market Size & Forecast
 - 10.3.2.1.1.□By Value
 - 10.3.2.2.□Market Share & Forecast
 - 10.3.2.2.1.□By Valence
 - 10.3.2.2.2.□By Disease Indication
 - 10.3.2.2.3.□By Distribution Channel
- 10.3.3.□United Kingdom Human Papillomavirus Vaccine Market Outlook
 - 10.3.3.1.□Market Size & Forecast
 - 10.3.3.1.1.□By Value
 - 10.3.3.2.□Market Share & Forecast
 - 10.3.3.2.1.□By Valence
 - 10.3.3.2.2.□By Disease Indication
 - 10.3.3.2.3.□By Distribution Channel
- 10.3.4.□Italy Human Papillomavirus Vaccine Market Outlook
 - 10.3.4.1.□Market Size & Forecast
 - 10.3.4.1.1.□By Value
 - 10.3.4.2.□Market Share & Forecast
 - 10.3.4.2.1.□By Valence
 - 10.3.4.2.2.□By Disease Indication
 - 10.3.4.2.3.□By Distribution Channel
- 10.3.5.□Spain Human Papillomavirus Vaccine Market Outlook
 - 10.3.5.1.□Market Size & Forecast
 - 10.3.5.1.1.□By Value
 - 10.3.5.2.□Market Share & Forecast
 - 10.3.5.2.1.□By Valence
 - 10.3.5.2.2.□By Disease Indication
 - 10.3.5.2.3.□By Distribution Channel
- 11.□Asia-Pacific Human Papillomavirus Vaccine Market Outlook
 - 11.1.□Market Size & Forecast□
 - 11.1.1.□By Value
 - 11.2.□Market Share & Forecast
 - 11.2.1.□By Valence
 - 11.2.2.□By Disease Indication
 - 11.2.3.□By Distribution Channel
 - 11.2.4.□By Country
 - 11.3.□Asia-Pacific: Country Analysis
 - 11.3.1.□China Human Papillomavirus Vaccine Market Outlook
 - 11.3.1.1.□Market Size & Forecast
 - 11.3.1.1.1.□By Value
 - 11.3.1.2.□Market Share & Forecast
 - 11.3.1.2.1.□By Valence
 - 11.3.1.2.2.□By Disease Indication

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.3.1.2.3. By Distribution Channel
- 11.3.2. India Human Papillomavirus Vaccine Market Outlook
 - 11.3.2.1. Market Size & Forecast
 - 11.3.2.1.1. By Value
 - 11.3.2.2. Market Share & Forecast
 - 11.3.2.2.1. By Valence
 - 11.3.2.2.2. By Disease Indication
 - 11.3.2.2.3. By Distribution Channel
- 11.3.3. Japan Human Papillomavirus Vaccine Market Outlook
 - 11.3.3.1. Market Size & Forecast
 - 11.3.3.1.1. By Value
 - 11.3.3.2. Market Share & Forecast
 - 11.3.3.2.1. By Valence
 - 11.3.3.2.2. By Disease Indication
 - 11.3.3.2.3. By Distribution Channel
- 11.3.4. South Korea Human Papillomavirus Vaccine Market Outlook
 - 11.3.4.1. Market Size & Forecast
 - 11.3.4.1.1. By Value
 - 11.3.4.2. Market Share & Forecast
 - 11.3.4.2.1. By Valence
 - 11.3.4.2.2. By Disease Indication
 - 11.3.4.2.3. By Distribution Channel
- 11.3.5. Australia Human Papillomavirus Vaccine Market Outlook
 - 11.3.5.1. Market Size & Forecast
 - 11.3.5.1.1. By Value
 - 11.3.5.2. Market Share & Forecast
 - 11.3.5.2.1. By Valence
 - 11.3.5.2.2. By Disease Indication
 - 11.3.5.2.3. By Distribution Channel
- 12. South America Human Papillomavirus Vaccine Market Outlook
 - 12.1. Market Size & Forecast
 - 12.1.1. By Value
 - 12.2. Market Share & Forecast
 - 12.2.1. By Valence
 - 12.2.2. By Disease Indication
 - 12.2.3. By Distribution Channel
 - 12.2.4. By Country
 - 12.3. South America: Country Analysis
 - 12.3.1. Brazil Human Papillomavirus Vaccine Market Outlook
 - 12.3.1.1. Market Size & Forecast
 - 12.3.1.1.1. By Value
 - 12.3.1.2. Market Share & Forecast
 - 12.3.1.2.1. By Valence
 - 12.3.1.2.2. By Disease Indication
 - 12.3.1.2.3. By Distribution Channel
 - 12.3.2. Argentina Human Papillomavirus Vaccine Market Outlook
 - 12.3.2.1. Market Size & Forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.3.2.1.1. By Value
- 12.3.2.2. Market Share & Forecast
 - 12.3.2.2.1. By Valence
 - 12.3.2.2.2. By Disease Indication
 - 12.3.2.2.3. By Distribution Channel
- 12.3.3. Colombia Human Papillomavirus Vaccine Market Outlook
 - 12.3.3.1. Market Size & Forecast
 - 12.3.3.1.1. By Value
 - 12.3.3.2. Market Share & Forecast
 - 12.3.3.2.1. By Valence
 - 12.3.3.2.2. By Disease Indication
 - 12.3.3.2.3. By Distribution Channel
- 13. Middle East and Africa Human Papillomavirus Vaccine Market Outlook
 - 13.1. Market Size & Forecast
 - 13.1.1. By Value
 - 13.2. Market Share & Forecast
 - 13.2.1. By Valence
 - 13.2.2. By Disease Indication
 - 13.2.3. By Distribution Channel
 - 13.2.4. By Country
 - 13.3. MEA: Country Analysis
 - 13.3.1. South Africa Human Papillomavirus Vaccine Market Outlook
 - 13.3.1.1. Market Size & Forecast
 - 13.3.1.1.1. By Value
 - 13.3.1.2. Market Share & Forecast
 - 13.3.1.2.1. By Valence
 - 13.3.1.2.2. By Disease Indication
 - 13.3.1.2.3. By Distribution Channel
 - 13.3.2. Saudi Arabia Human Papillomavirus Vaccine Market Outlook
 - 13.3.2.1. Market Size & Forecast
 - 13.3.2.1.1. By Value
 - 13.3.2.2. Market Share & Forecast
 - 13.3.2.2.1. By Valence
 - 13.3.2.2.2. By Disease Indication
 - 13.3.2.2.3. By Distribution Channel
 - 13.3.3. UAE Human Papillomavirus Vaccine Market Outlook
 - 13.3.3.1. Market Size & Forecast
 - 13.3.3.1.1. By Value
 - 13.3.3.2. Market Share & Forecast
 - 13.3.3.2.1. By Valence
 - 13.3.3.2.2. By Disease Indication
 - 13.3.3.2.3. By Distribution Channel
- 14. Market Dynamics
 - 14.1. Drivers
 - 14.2. Challenges
- 15. Market Trends & Developments
- 16. Competitive Landscape

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.1. Serum Institute of India Pvt. Ltd.
- 16.2. GlaxoSmithKline Plc.
- 16.3. Johnson & Johnson
- 16.4. Merck & Co., Inc.
- 16.5. AstraZeneca Plc
- 16.6. Novartis AG
- 16.7. Inovio Pharmaceuticals, Inc.
- 16.8. Xenetic Biosciences, Inc.
- 16.9. Sanofi SA
- 16.10. Bharat Biotech International Limited
17. Strategic Recommendations

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027
Segmented By Valence (Bivalent, Quadrivalent, Nonvalent, Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others), By Company and By Region

Market Report | 2022-12-01 | 113 pages | TechSci Research

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4900.00
	Multi-User License	\$5900.00
	Custom Research License	\$8900.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*

Phone*

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com